PDCD1 and neoplasm: (2) Evaluation of early tumor response using Choi and rChoi instead of RECIST 1.1 and mRECIST significantly correlated with the OS of patients with uHCC treated with an anti-PD-1 antibody plus anti-angiogenesis targeted therapy.